Clinical trials: sponsored by Acerta Pharma BV
Chronic Lymphocytic Leukemia
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02970318
- Testing
- Acalabrutinib (ACP-196), Rituximab, Idelalisib
- Where
- 157 sites in United States, Australia and 23 more
- Volunteers
- 310 people
- Sponsor
- Acerta Pharma BV
Diffuse Large B-Cell Lymphoma
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects…
- Trial name
- ESCALADE (NCT04529772)
- Testing
- acalabrutinib, Prednisone, Rituximab
- Where
- 245 sites in United States, Australia and 21 more
- Volunteers
- 611 people
- Sponsor
- Acerta Pharma BV
Lymphoma, Mantle Cell
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.
- Trial name
- NCT02972840
- Testing
- Acalabrutinib, Bendamustine, Rituximab
- Where
- 228 sites in United States, Argentina and 25 more
- Volunteers
- 635 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in…
- Trial name
- AMPLIFY (NCT03836261)
- Testing
- Acalabrutinib, Venetoclax, Chemoimmunotherapy
- Where
- 169 sites in United States, Argentina and 25 more
- Volunteers
- 984 people
- Sponsor
- Acerta Pharma BV
Non Hodgkin Lymphoma
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects…
- Trial name
- NCT02180711
- Testing
- acalabrutinib, rituximab (IV), Lenalidomide
- Where
- 29 sites in United States, Canada and 1 more
- Volunteers
- 113 people
- Sponsor
- Acerta Pharma BV
Waldenström Macroglobulinemia (WM)
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.
- Trial name
- NCT02180724
- Testing
- Acalabrutinib (ACP-196)
- Where
- 38 sites in United States, France and 5 more
- Volunteers
- 107 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.
- Trial name
- NCT02477696
- Testing
- Acalabrutinib, Ibrutinib
- Where
- 130 sites in United States, Australia and 13 more
- Volunteers
- 533 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic…
- Trial name
- ElevateTN (NCT02475681)
- Testing
- Acalabrutinib, Obinutuzumab, Chlorambucil
- Where
- 155 sites in United States, Australia and 16 more
- Volunteers
- 535 people
- Sponsor
- Acerta Pharma BV
Mantle Cell Lymphoma (MCL)
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
- Trial name
- NCT02213926
- Testing
- ACP-196 (acalabrutinib)
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 124 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT02337829
- Testing
- Acalabrutinib (Arm A), Acalabrutinib (Arm B)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
This study evaluates the safety, pharmacokinetics, pharmacodynamics and efficacy of acalabrutinib and ceralasertib (known as AZD6738) when taken in combination.
- Trial name
- NCT03328273
- Testing
- Ceralasertib, Acalabrutinib
- Where
- 11 sites in Poland, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Acerta Pharma BV
Mantle Cell Lymphoma (MCL)
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma
- Trial name
- NCT02717624
- Testing
- Acalabrutinib in combination with BR, Acalabrutinib in combination with VR
- Where
- 15 sites in United States, Italy and 1 more
- Volunteers
- 72 people
- Sponsor
- Acerta Pharma BV
Follicular Lymphoma (FL), CLL
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
- Conditions
- Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome
- Trial name
- KEYNOTE145 (NCT02362035)
- Testing
- Acalabrutinib, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 161 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
- Trial name
- NCT02029443
- Testing
- Acalabrutinib
- Where
- 12 sites in United States, Italy and 1 more
- Volunteers
- 306 people
- Sponsor
- Acerta Pharma BV
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
- Trial name
- NCT02717611
- Testing
- ACP-196 (acalabrutinib)
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
To evaluate the safety and preliminary efficacy of acalabrutinib in combination with obinutuzumab in 4 separate cohorts of participants.
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
- Trial name
- NCT02296918
- Testing
- acalabrutinib, Obinutuzumab, Venetoclax
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Acerta Pharma BV
Non-Hodgkins Lymphoma, Multiple Myeloma
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy acalabrutinib and ACP 319 in B-cell malignancies.
- Conditions
- Non-Hodgkins Lymphoma, Multiple Myeloma, B-All
- Trial name
- NCT02328014
- Testing
- Acalabrutinib, ACP-319
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
- Trial name
- NCT02157324
- Testing
- acalabrutinib, ACP-319
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Acerta Pharma BV
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).
- Trial name
- NCT02112526
- Testing
- Acalabrutinib
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 21 people
- Sponsor
- Acerta Pharma BV